Anti-SARS-CoV-2 Spike RBD (Clone: 2355)

Antibody Details

Product Details

Reactivity Species

SARS-CoV-2

⋅

Virus

Expression Host

HEK-293

Immunogen

Sequenced from human survivors of COVID-19 (SARS-CoV-2)

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

Formulation

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Standard Overnight on Blue Ice.

RRID

AB_2893962

Applications and Recommended Usage?
Quality Tested by Leinco

ELISA
N

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Anti-SARS-CoV-2 Spike RBD, clone 2355, specifically targets an epitope on the SARS-CoV-2 spike protein receptor-binding domain (RBD).

Antigen Distribution

The spike RBD is expressed on the surface of SARS-CoV-2.

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family ¹. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) ². The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells ³. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells ^3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV ^{3, 6}. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the “down” or “up” conformations, which hide or expose the receptor-binding motifs, respectively ⁷. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion ^{8, 9}.




Polyclonal RBD-specific antibodies can block ACE2 binding ^{10, 11}, and anti-RBD neutralizing antibodies are present in the sera of convalescent COVID19 patients ¹², identifying the RBD as an attractive candidate for vaccines and therapeutics. In addition, the RBD is poorly conserved, making it a promising antigen for diagnostic tests ^{13 14}. Serologic tests for the RBD are highly sensitive and specific for detecting SARS-CoV-2 antibodies in COVID19 patients ^{13 15}. Furthermore, the levels of anti-RBD antibodies correlated with SARS-CoV-2 neutralizing antibodies, suggesting the RBD could be used to predict an individual's risk of disease ¹³.

Antigen Details

Protein

SARS-CoV-2 RBD

PubMed

SARS-CoV-2 RBD

Research Area

COVID-19

.

Viral

References & Citations

1.Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.

2.Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.

3.Wrapp D, Wang N, Corbett KS, et al. bioRxiv. 2020.02.11.944462. 2020.

4.Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Cell. 181(2):281-292.e6. 2020.

5.Li W, Zhang C, Sui J, et al. EMBO J. 24(8):1634-1643. 2005.

6.Shang, J., Ye, G., Shi, K. et al. Nature 581, 221–224. 2020.

7.Gui M, Song W, Zhou H, et al. Cell Res. 27(1):119-129. 2017.

8.Walls AC, Tortorici MA, Snijder J, et al. Proc Natl Acad Sci U S A. 114(42):11157-11162. 2017.

9.Hoffmann M, Kleine-Weber H, Schroeder S, et al. Cell. 181(2):271-280.e8. 2020.

10.Huo J, Zhao Y, Ren J, et al. Cell Host Microbe. S1931-3128(20)30351-6. 2020.

11.Tai, W., He, L., Zhang, X. et al. Cell Mol Immunol 17, 613–620. 2020.

12.Cao Y, Su B, Guo X, et al. Cell. 182(1):73-84.e16. 2020.

13.Premkumar L, Segovia-Chumbez B, Jadi R, et al. medRxiv; 2020.

14.Quinlan BD, Mou H, Zhang L, et al. bioRxiv; 2020.

15.Olba NM, Muller MA, Li W, et al. medRxiv; 2020.

Technical Protocols